Search the Newsreel

Price-Driven Insight from (CRBP) for Rule-Based Strategy

This article provides a price-driven insight for Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), outlining near-term and mid-term strong sentiment but a weak long-term outlook. It details specific trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance …

Bernstein Lifts Regeneron Price Target to $756, Stays on Sidelines

Bernstein has raised its price target for Regeneron Pharmaceuticals to $756 from $753, while maintaining a Market Perform rating, indicating a slightly more positive near-term outlook but not a fundamental shift in its investment thesis. This new target remains below the Wall Street consensus …

Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake

CVI Investments, Inc. and Heights Capital Management, Inc. have reported a beneficial ownership of 3,008,529 common shares in Citius Pharmaceuticals (CTXR), which represents a 9.9% stake. This position primarily consists of shares issuable upon the exercise of warrants, subject to beneficial ownership limits of …

Zenas BioPharma (ZBIO) Is Down 9.2% After Wider Losses And Leadership Changes - What's Changed

Zenas BioPharma reported widening losses in Q2 2026, with revenue dropping significantly year-over-year and net loss reaching US$111,460,000. These financial results were accompanied by leadership changes, including the CFO transitioning to a Strategic Advisor role and a new board appointment. The company's investment narrative …

Immupharma Stock Price Forecast. Should You Buy IMM.L?

Lantern Pharma (LTRN) Advances AI-Driven Oncology Pipeline Amid Valuation Challenges

Anuh Pharma Shareholders Clear Board Reappointments and Governance Updates

This Analyst Believes Eton Pharma’s Raised Guidance Is ‘Conservative’ – ETON Stock Heads For Best Ever Day

Eton Pharmaceuticals (ETON) shares surged 40% to an all-time high after better-than-expected Q2 results, driven by the successful relaunch of Hemangeol. The company raised its full-year 2026 revenue guidance to over $145 million and adjusted EBITDA margin to at least 35%. Analysts from B. …

Aspire BioPharma, Inc. (NASDAQ: ASBP) Share Price, ASBP Stock News, ASBP Share Price & Updates

Traws Pharma (TRAW) investor Squadron reports 0% beneficial ownership in 13G/A

Squadron Master Fund LP, Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank have filed an amended Schedule 13G (Amendment No. 4) for Traws Pharma (TRAW), reporting 0% beneficial ownership. The group now holds no shares of Traws Pharma common stock and possesses no …

ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth

ANI Pharmaceuticals, Inc. ANIP topped second-quarter earnings and revenue expectations, but the quarter also exposed a softer result for Cortrophin Gel, its key growth driver. That tension matters because Cortrophin now carries more weight in the company's growth mix. ANI kept its broader 2026 …

Innate Pharma increases equity bookbuild by a third to €30m

Innate Pharma has increased its equity bookbuild by one-third to €30 million, driven by a new $75 million partnership to develop a lymphoma treatment. The article indicates that this partnership was a significant "catalyst for investors." The full details are available to subscribers of …

Mereo BioPharma (MREO): EcoR1 reports 0.6% passive stake via ADS holdings

EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have reported a passive beneficial ownership of 0.6% each in Mereo BioPharma Group plc. This stake, held through American Depositary Shares (ADS), represents 5,000,000 Ordinary Shares for EcoR1 and Nodelman, and 4,732,750 Ordinary …

Lantern Pharma outlines Open Medicine AI spin-out amid $10B market outlook by 2030-2031

Earnings Call Insights: Lantern Pharma (LTRN) Q2 2026 MANAGEMENT VIEW * “In August, we established Open Medicine AI as a separate company with commercial licenses and agreements with Lantern in place to take the AI data models to the next level,” said (President, CEO …

Immix Biopharma (NASDAQ:IMMX) Stock Price Down 4.5% - Here's Why

Immix Biopharma (NASDAQ: IMMX) shares dropped 4.5% to $10.43 on Friday, with trading volume significantly below average. This decline followed the company missing its latest quarterly earnings estimate, reporting a loss of $0.18 per share against an expected $0.17 loss. Despite the recent dip, …

Pharma Mar, S.A. : Top Fondos de inversión | PHM | ES0169501022

Pharma Mar, S.A. : Consenso de Precios Objetivo y Recomendaciones de los Analistas | PHM | ES0169501022

ETON Stock Soars After Huge Earnings Beat And Guidance Hike

Eton Pharmaceuticals (ETON) stock surged by over 40% after reporting Q2 revenue of $37.6 million, nearly double year-over-year and significantly beating consensus estimates, with adjusted EPS of $0.43. Management raised its 2026 revenue guidance to over $145 million and adjusted EBITDA margin to at …

Curanex Pharmaceuticals Inc Q2 2026: Net income $(3.29M), EPS $(0.12) — 10-Q Summary

Curanex Pharmaceuticals Inc (CURX) reported a net loss of $(3.29M) for Q2 2026, with a diluted loss per share of $(0.12), and no revenue as the company remains pre-revenue. This compares to a net loss of $(0.06M) in Q2 2025. The company completed a …

CURX: Net loss rose to $6.4M as R&D spending increased; cash shortfall raises going concern doubts

Curanex Pharmaceuticals Inc (CURX) reported a net loss of $6.4 million for the first half of 2026, primarily due to increased spending on R&D and administrative costs as its lead drug candidate progresses. The company faces significant going concern doubts as its current cash …

Conferencia de resultados del T2 de 2026 de Acumen Pharmaceuticals (ABOS): lectura de datos de ALTITUDE-AD prevista para finales de 2026

Acumen Pharmaceuticals (NASDAQ: ABOS) held its Q2 2026 earnings conference call, focusing on the upcoming Phase II ALTITUDE-AD trial results for sabirnetug, expected by late 2026. The company reported $110.2 million in cash and marketable securities, providing liquidity until early 2027, with a net …

Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice

Urogen Pharma (URGN) is highlighted as a strong momentum pick due to its "A" Momentum Style Score from Zacks and a Zacks Rank of #2 (Buy). The article details URGN's impressive short-term and long-term price performance, outperforming both its industry and the S&P 500. …

Eton Pharmaceuticals Stock Jumps 38% as Guidance Reset Tests Valuation

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Cue Biopharma reported its second-quarter 2026 financial results, highlighting a significant increase in revenue due to a collaboration milestone and higher expenses related to the CUE-221 development program. The company also announced the submission of an IND for CUE-221 in food allergy applications, a …

ABIONYX Pharma SA: Objectif de Cours et Consensus des Analystes | ABNX | FR0012616852

Aquamarine Financial (ORMP) discloses 6.04% Oramed ownership in 13G/A

Aquamarine Financial (Cayman) Ltd has reported a beneficial ownership of 2,512,175 shares in Oramed Pharmaceuticals Inc., which constitutes 6.04% of the common stock as of June 30, 2026. The filing, an amended Schedule 13G/A, indicates that Aquamarine holds sole voting and sole dispositive power …

Immix Biopharma (IMMX) gains 5.6% stake holder led by Eventide Asset Management

Eventide Asset Management, LLC, through its Eventide Healthcare & Life Sciences Fund, has reported a beneficial ownership of 3,891,019 shares of Immix Biopharma (IMMX) common stock, representing a 5.6% stake. This Schedule 13G filing indicates that Eventide holds sole voting and dispositive power over …

ALNY Maintains Equal-Weight by Wells Fargo -- Price Target Lowered to $256

Wells Fargo has maintained an Equal-Weight rating for Alnylam Pharmaceuticals (ALNY), lowering its price target from $316.00 to $256.00, an 18.99% decrease. Despite this, GuruFocus indicates ALNY is significantly undervalued at $223.22 compared to its GF Value™ of $528.81, showing a 57.8% undervaluation and …

West Pharmaceutical (WST) Upgraded to Buy: Here's Why

West Pharmaceutical (WST) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This upgrade suggests a positive outlook for the company's underlying business and could lead to a favorable impact on its stock price. The …

Eton Pharmaceuticals: No Reason Pharma Can't Deliver More Great Earnings Like These

BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.

One of the more high-flying stocks in the U.S. biotech sector these days is genetic-disease-focused BridgeBio Pharma (NASDAQ: BBIO). That's due almost entirely to the outperformance of its Attruby heart medication. If the generally bullish analyst sentiment on the company is anything to go …

What's Going On With Medipharm Labs Corp Stock Friday?

Ascendis Pharma Reports Solid Yorvipath Quarter; Yuviwel Off to Strong Start, RBC Says

Ascendis Pharma's (ASND) Q2 results showed a solid rebound for Yorvipath, while the early launch of Yuviwel in achondroplasia is progressing well, RBC Capital Markets said in a Thursday note.According to the note, Yorvipath revenue rose to 252 million euros ($291.8 million) from Silver …

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Inovio Pharmaceuticals Inc. (INO) shares surged 21.10% to $1.09 on Friday, outperforming the broader market as the NASDAQ Composite Index and Dow Jones Industrial Average both experienced declines. This marked the fifth consecutive day of gains for Inovio's stock, despite a generally rough trading …

BridgeBio Pharma's Transition to Rare Disease 'Commercial Powerhouse' On Track, RBC Says

BridgeBio Pharma's (BBIO) transition into a rare disease "commercial powerhouse" is on track and poised to accelerate, RBC Capital Markets said in a Friday note.The company's Attruby drug is gaining traction in first-line treatment settings, while the market for the drug Silver Upgrade to …

Amneal Pharmaceuticals Director John Kiely Sells 50,000 Shares and Donates 10,000 Shares on August 13, 2026

John Kiely, a director at Amneal Pharmaceuticals (NASDAQ: AMRX), sold 50,000 shares of Class A Common Stock at an average price of $17.64 and donated 10,000 shares to a donor-advised fund on August 13, 2026. After these transactions, Kiely's direct ownership in the company …